Arphra/Issuer/VRTX

VRTX

Vertex Pharmaceuticals Incorporated

HealthcareBiotechnologyUSUSD

$434.16

+0.50%LiveJun 01, 2026

AI Brief

Market cap

$110.19B

52w range

362.50 – 507.92

P / E

—

EPS

—

Volume

274.7K

Revenue · FY

$12.07B

+9.57% YoY

Explain this page

Arphra AIPlain-English read on Vertex Pharmaceuticals Incorporated’s valuation

AI Issuer Brief

Arphra AI

Loading cached brief…

Insider · 30d

Bought

0 txns

Sold

$8.21M

10 txns

Net flow

−$8.21M

Full history →

Price

DB · prices_daily

1M 6M 1Y 5Y

Last

$425.84

Change

-4.40%

Period high

$499.17

Period low

$366.54

Period start

$445.432025-06-02

Through 2026-05-04

Peers

Price change · trailing returns

Live

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
-2.99%	-0.99%	+2.42%	-12.61%	+2.01%	-4.24%	-2.53%	+34.16%	+107.07%	+362.36%	+9548.00%

Aftermarket

Live

Jun 01, 03:27 PM

Last trade

$434.16

2 sh

Bid

$434.00

21 sh

Ask

$434.32

60 sh

Spread

$0.320

Sector & industry today

Live

Sectors

Technology
+3.05%
Energy
+1.38%
Industrials
-0.37%
Real Estate
-0.38%
Communication Services
-0.39%
Consumer Cyclical
-0.53%
Basic Materials
-0.63%
Consumer Defensive
-0.64%
Financial Services
-0.75%
Healthcare
-0.81%
Utilities
-1.21%

Top industries (issuer's industry highlighted)

Biotechnology
-2.64%
Computer Hardware
+7.46%
Coal
+4.33%
Semiconductors
+4.06%
Luxury Goods
-3.55%
Electronic Gaming & Multimedia
-3.53%
Paper, Lumber & Forest Products
-2.65%
Integrated Freight & Logistics
+2.54%
Agricultural Farm Products
+2.52%
Software - Infrastructure
+2.47%
Internet Content & Information
-2.15%
Oil & Gas Refining & Marketing
+2.12%

Fair value

Football field →

Weighted blend

$2,147.58

+394.65% vs spot

Recommendation

Strong Buy

15 of 16 methods

Method spread

4bull11bear

±5% threshold

Analyst PT consensus: $552.27 (+27.20%)

Total assets

$26.14B

Total debt

$3.88B

Cash & equiv

$5.09B

Operating CF

$3.63B

Free cash flow

$3.19B

Buybacks

-$2.02B

Analyst view

DB · price_targets + analyst_grades

Consensus target

$552.27

+27.20% upside

Low

$437.00

Median

$558.00

High

$612.00

Recent actions

0 ↑0 ↓8 hold

Apr 01, 2026
Mar 01, 2026
Feb 01, 2026
Jan 01, 2026
Dec 01, 2025

News

DB · news_items

Recent quarters

All financials →

Period	Revenue	Net income	EPS
Q4 Dec 2025	$3.23B	$1.19B	$4.65
Q3 Sep 2025	$3.08B	$1.08B	$4.20
Q2 Jun 2025	$2.96B	$1.03B	$3.99
Q1 Mar 2025	$2.77B	$646.3M	$2.49
Q4 Dec 2024	$2.91B	$913M	$3.50
Q3 Sep 2024	$2.77B	$1.05B	$4.01

Recent insiders

All →

Insider	Action	Shares	Value	Date
Bhatia Sangeeta N. director	Sell	318	$134.75K	May 04, 2026
Liu Joy officer: EVP and Chief Legal Officer	Sell	1,104	$469.22K	May 01, 2026
Liu Joy officer: EVP and Chief Legal Officer	Sell	978	$439.29K	Apr 01, 2026
Bozic Carmen officer: EVP and CMO	Sell	2,329	$1.05M	Mar 27, 2026
Bozic Carmen officer: EVP and CMO	Sell	2,329	$1.12M	Mar 13, 2026
McKechnie Duncan officer: EVP, Chief Commercial Officer	Sell	2,633	$1.31M	Mar 11, 2026

Income statement · annual

Open Financials →

Period	Revenue	Op income	Net income	EPS	Net margin
FY 2025	$12.07B	$4.76B	$3.95B	$15.32	+32.74%
FY 2024	$11.02B	-$232.9M	-$535.6M	$-2.08	-4.86%
FY 2023	$9.87B	$3.83B	$3.62B	$13.89	+36.68%
FY 2022	$8.93B	$4.31B	$3.32B	$12.82	+37.20%
FY 2021	$7.57B	$2.78B	$2.34B	$9.01	+30.92%